Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FGFR2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FGFR2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FGFR2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FGFR2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FGFR2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FGFR2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FGFR2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FGFR2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FGFR2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FGFR2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00018371 | Colorectum | CRC | epithelial to mesenchymal transition | 30/2078 | 157/18723 | 2.06e-03 | 2.05e-02 | 30 |
GO:00721753 | Colorectum | CRC | epithelial tube formation | 26/2078 | 132/18723 | 2.56e-03 | 2.40e-02 | 26 |
GO:00487551 | Colorectum | CRC | branching morphogenesis of a nerve | 5/2078 | 10/18723 | 2.61e-03 | 2.40e-02 | 5 |
GO:00015034 | Colorectum | CRC | ossification | 64/2078 | 408/18723 | 2.73e-03 | 2.49e-02 | 64 |
GO:00973054 | Colorectum | CRC | response to alcohol | 43/2078 | 253/18723 | 2.96e-03 | 2.66e-02 | 43 |
GO:0021872 | Colorectum | CRC | forebrain generation of neurons | 13/2078 | 51/18723 | 3.09e-03 | 2.73e-02 | 13 |
GO:0060537 | Colorectum | CRC | muscle tissue development | 63/2078 | 403/18723 | 3.17e-03 | 2.78e-02 | 63 |
GO:00436163 | Colorectum | CRC | keratinocyte proliferation | 12/2078 | 46/18723 | 3.58e-03 | 3.03e-02 | 12 |
GO:00108373 | Colorectum | CRC | regulation of keratinocyte proliferation | 10/2078 | 35/18723 | 3.74e-03 | 3.14e-02 | 10 |
GO:00032791 | Colorectum | CRC | cardiac septum development | 21/2078 | 103/18723 | 4.15e-03 | 3.40e-02 | 21 |
GO:00032811 | Colorectum | CRC | ventricular septum development | 16/2078 | 71/18723 | 4.22e-03 | 3.44e-02 | 16 |
GO:00308794 | Colorectum | CRC | mammary gland development | 26/2078 | 137/18723 | 4.32e-03 | 3.47e-02 | 26 |
GO:0060174 | Colorectum | CRC | limb bud formation | 5/2078 | 11/18723 | 4.35e-03 | 3.47e-02 | 5 |
GO:00224041 | Colorectum | CRC | molting cycle process | 18/2078 | 84/18723 | 4.43e-03 | 3.47e-02 | 18 |
GO:00224051 | Colorectum | CRC | hair cycle process | 18/2078 | 84/18723 | 4.43e-03 | 3.47e-02 | 18 |
GO:0043410 | Colorectum | CRC | positive regulation of MAPK cascade | 72/2078 | 480/18723 | 4.85e-03 | 3.74e-02 | 72 |
GO:00485683 | Colorectum | CRC | embryonic organ development | 65/2078 | 427/18723 | 5.15e-03 | 3.94e-02 | 65 |
GO:0060541 | Colorectum | CRC | respiratory system development | 35/2078 | 203/18723 | 5.45e-03 | 4.12e-02 | 35 |
GO:00017014 | Colorectum | CRC | in utero embryonic development | 57/2078 | 367/18723 | 5.54e-03 | 4.19e-02 | 57 |
GO:00032051 | Colorectum | CRC | cardiac chamber development | 29/2078 | 161/18723 | 5.82e-03 | 4.32e-02 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGFR2 | SNV | Missense_Mutation | rs779423644 | c.364G>A | p.Val122Met | p.V122M | P21802 | protein_coding | deleterious(0.01) | possibly_damaging(0.902) | TCGA-3C-AALJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FGFR2 | SNV | Missense_Mutation | | c.338N>C | p.Val113Ala | p.V113A | P21802 | protein_coding | tolerated(0.52) | benign(0.1) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
FGFR2 | SNV | Missense_Mutation | | c.1763N>G | p.Ser588Cys | p.S588C | P21802 | protein_coding | tolerated(0.31) | possibly_damaging(0.857) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | | c.785N>C | p.Leu262Pro | p.L262P | P21802 | protein_coding | deleterious(0.01) | probably_damaging(0.937) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | novel | c.1904N>C | p.Val635Ala | p.V635A | P21802 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | rs121913474 | c.1147T>C | p.Cys383Arg | p.C383R | P21802 | protein_coding | deleterious(0.02) | possibly_damaging(0.865) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | | c.1650T>G | p.Asn550Lys | p.N550K | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | | c.1099N>C | p.Glu367Gln | p.E367Q | P21802 | protein_coding | tolerated(0.19) | benign(0.156) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
FGFR2 | SNV | Missense_Mutation | rs121913476 | c.1650T>A | p.Asn550Lys | p.N550K | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
FGFR2 | SNV | Missense_Mutation | | c.1414G>T | p.Asp472Tyr | p.D472Y | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | | AZ6089 | | 22869148 |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | | CVBT-141H | | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | BGJ398 | INFIGRATINIB | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | | DOVITINIB | DOVITINIB | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | 252827519 | | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | | TRAFERMIN | TRAFERMIN | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | NINTEDANIB | NINTEDANIB | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | | Trametinib | TRAMETINIB | 27338794 |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | CHEMBL1852688 | INFIGRATINIB | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | LENVATINIB | LENVATINIB | |